Literature DB >> 7654483

Use of 24 h ambulatory ECG recordings in the assessment of new chemical entities in healthy volunteers.

J C Stinson1, J S Pears, A J Williams, R W Campbell.   

Abstract

1. Ambulatory (24 h) cardiac monitoring (ACM) is frequently used to screen healthy volunteers before inclusion in trials of new chemical entities in man. We analysed 156 consecutive ACM recordings in 'healthy' volunteers (on no medication). 2. Only 20 (13%) of the recordings showed normal sinus rhythm throughout. 3. Supraventricular ectopics were the commonest abnormality (83%). Ventricular ectopics occurred in 11%; ventricular tachycardia (unsustained) in 2% and sinus pauses in 6.5%. One volunteer was found to be in atrial fibrillation throughout. 4. The data indicate that when ACM recordings are performed in the assessment of the effects of experimental drugs, guidelines are needed to assess 'normality' to suggest when cardiological investigation is needed and to assign causality of the arrhythmia to the new chemical entity. 5. Proposed guidelines are presented.

Entities:  

Mesh:

Year:  1995        PMID: 7654483      PMCID: PMC1365077          DOI: 10.1111/j.1365-2125.1995.tb05724.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  22 in total

1.  Long-term recording of the electrocardiogram in a normal population.

Authors:  E B Raftery; P M Cashman
Journal:  Postgrad Med J       Date:  1976       Impact factor: 2.401

2.  Predictive value of ventricular premature beats for subsequent ischaemic heart disease in apparently healthy subjects.

Authors:  P Bjerregaard; K E Sorensen; H Molgaard
Journal:  Eur Heart J       Date:  1991-05       Impact factor: 29.983

3.  Frequency of extrasystoles in healthy male employees.

Authors:  K Orth-Gomér; C Hogstedt; L Bodin; B Söderholm
Journal:  Br Heart J       Date:  1986-03

4.  Long-term follow-up of asymptomatic healthy subjects with frequent and complex ventricular ectopy.

Authors:  H L Kennedy; J A Whitlock; M K Sprague; L J Kennedy; T A Buckingham; R J Goldberg
Journal:  N Engl J Med       Date:  1985-01-24       Impact factor: 91.245

Review 5.  Programmed electrical stimulation: its role in the management of ventricular arrhythmias in coronary heart disease.

Authors:  H J Wellens; P Brugada; W G Stevenson
Journal:  Prog Cardiovasc Dis       Date:  1986 Nov-Dec       Impact factor: 8.194

6.  Flosequinan and arrhythmogenesis.

Authors:  J Noble; M Farrer; J M McComb
Journal:  Lancet       Date:  1993-04-24       Impact factor: 79.321

7.  Incidence and prognostic significance of ventricular arrhythmias in individuals without detectable heart disease.

Authors:  K P Bethge; D Bethge; G Meiners; P R Lichtlen
Journal:  Eur Heart J       Date:  1983-05       Impact factor: 29.983

8.  Prognostic factors in nonsustained ventricular tachycardia.

Authors:  A E Buxton; F E Marchlinski; H L Waxman; B T Flores; D M Cassidy; M E Josephson
Journal:  Am J Cardiol       Date:  1984-05-01       Impact factor: 2.778

Review 9.  Investigation of palpitations.

Authors:  P Brugada; S Gürsoy; J Brugada; E Andries
Journal:  Lancet       Date:  1993-05-15       Impact factor: 79.321

10.  Objective evidence of occult myocardial dysfunction in patients with frequent ventricular ectopy without clinically apparent heart disease.

Authors:  H L Kennedy; J E Pescarmona; R J Bouchard; R J Goldberg; D G Caralis
Journal:  Am Heart J       Date:  1982-07       Impact factor: 4.749

View more
  8 in total

1.  The prevalence and incidence of medical conditions in healthy pharmaceutical company employees who volunteer to participate in medical research.

Authors:  S D Singh; A J Williams
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

2.  Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer.

Authors:  C J Punt; E E Voest; E Tueni; A T Van Oosterom; A Backx; P H De Mulder; B Hecquet; C Lucas; B Gerard; H Bleiberg
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

3.  Evaluation of the safety, pharmacokinetics, pharmacodynamics, and drug-drug interaction potential of a selective Lp-PLA2 inhibitor (GSK2647544) in healthy volunteers
.

Authors:  Kai Wu; Jianfeng Xu; Regan Fong; Xiaozhou Yao; Yanmei Xu; William Guiney; Frank Gray; Andrew Lockhart
Journal:  Int J Clin Pharmacol Ther       Date:  2016-12       Impact factor: 1.366

Review 4.  Who is a 'healthy subject'?-consensus results on pivotal eligibility criteria for clinical trials.

Authors:  Kerstin Breithaupt-Groegler; Christoph Coch; Martin Coenen; Frank Donath; Katharina Erb-Zohar; Klaus Francke; Karin Goehler; Mario Iovino; Klaus Peter Kammerer; Gerd Mikus; Jens Rengelshausen; Hildegard Sourgens; Reinhard Schinzel; Thomas Sudhop; Georg Wensing
Journal:  Eur J Clin Pharmacol       Date:  2017-01-07       Impact factor: 2.953

5.  Hidden burden of arrhythmias in patients with small atrial septal defects: a nationwide study.

Authors:  Sebastian Udholm; Camilla Nyboe; Andrew Redington; Jens Erik Nielsen-Kudsk; Jens Cosedis Nielsen; Vibeke Elisabeth Hjortdal
Journal:  Open Heart       Date:  2019-06-29

6.  Data driven evaluation of healthy volunteer characteristics at screening for phase I clinical trials to inform on study design and optimize screening processes.

Authors:  Annemie Deiteren; Erwin Coenen; Sabine Lenders; Peter Verwilst; Erik Mannaert; Freya Rasschaert
Journal:  Clin Transl Sci       Date:  2021-08-11       Impact factor: 4.689

7.  Morphological abnormalities in baseline ECGs in healthy normal volunteers participating in phase I studies.

Authors:  Pooja Hingorani; Mili Natekar; Sheetal Deshmukh; Dilip R Karnad; Snehal Kothari; Dhiraj Narula; Yash Lokhandwala
Journal:  Indian J Med Res       Date:  2012-03       Impact factor: 2.375

8.  Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β2 agonist vilanterol administered once daily for 52 weeks in patients >=12 years old with asthma: a randomised trial.

Authors:  William W Busse; Paul M O'Byrne; Eugene R Bleecker; Jan Lötvall; Ashley Woodcock; Leslie Andersen; Wesley Hicks; Jodie Crawford; Loretta Jacques; Ludovic Apoux; Eric D Bateman
Journal:  Thorax       Date:  2013-02-25       Impact factor: 9.139

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.